ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis

Published:2021-01 Issue:3 Volume:17 Page:349-357
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Yekedüz Emre¹²^ORCID,Köksoy Elif Berna¹²^ORCID,Akbulut Hakan¹²,Ürün Yüksel¹²^ORCID,Utkan Güngör¹²^ORCID

Affiliation:

1. Department of Medical Oncology, Ankara University, 06590, Cebeci/Ankara, Turkey

2. Ankara University Cancer Research Institute, 06590, Cebeci/Ankara, Turkey

Abstract

Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on 31 March 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0671

Reference25 articles.

1. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer

2. Circulating tumor DNA analysis in the era of precision oncology

3. A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations

4. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)

5. Biomarkers detecting minimal residual disease in solid tumors: what do they mean in the clinical management of patients?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy into the clinics: Current evidence and future perspectives;The Journal of Liquid Biopsy;2024-06

2. CtDNA’s prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review;Medicine;2023-02-10

3. Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta‐analysis;European Journal of Clinical Investigation;2022-07-28